ECSP034888A - Conjugados inmunogenicos de bajo peso molecular de acido halurónico con toxinas polipeptidas - Google Patents

Conjugados inmunogenicos de bajo peso molecular de acido halurónico con toxinas polipeptidas

Info

Publication number
ECSP034888A
ECSP034888A EC2003004888A ECSP034888A ECSP034888A EC SP034888 A ECSP034888 A EC SP034888A EC 2003004888 A EC2003004888 A EC 2003004888A EC SP034888 A ECSP034888 A EC SP034888A EC SP034888 A ECSP034888 A EC SP034888A
Authority
EC
Ecuador
Prior art keywords
molecular weight
streptococci
group
low
hyaluronic acid
Prior art date
Application number
EC2003004888A
Other languages
English (en)
Inventor
Francis Michon
Samuel Moore
Maryline Laude-Sharp
Milan Blake
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of ECSP034888A publication Critical patent/ECSP034888A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención provee composiciones antigénicas y métodos para el tratamiento y prevención de infecciones y enfermedades causadas por estreptococos de los grupos A y C. En particular la invención provee de ácido hialurónico de bajo peso molecular, unido a un portador y composiciones que los comprenden. Los compuestos obtienen anticuerpos de bajo peso molecular de ácido hialurónico los cuales son contra reactivos con los estreptococos de grupos A y C y que son mínimamente contra-reactivos con el ácido hialurónico nativo. La invención es particularmente útil para proveer protección inmunogénica tanto activa como pasiva en aquellos infectados o con riesgo de infección por estreptococos de grupos A y C. Adicionalmente la presente invención provee métodos y composiciones útiles para el diagnóstico de infecciones y enfermedades causadas por estreptococos de grupos A y C.
EC2003004888A 2001-05-11 2003-12-11 Conjugados inmunogenicos de bajo peso molecular de acido halurónico con toxinas polipeptidas ECSP034888A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/853,367 US20020192205A1 (en) 2001-05-11 2001-05-11 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci

Publications (1)

Publication Number Publication Date
ECSP034888A true ECSP034888A (es) 2004-05-28

Family

ID=25315838

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004888A ECSP034888A (es) 2001-05-11 2003-12-11 Conjugados inmunogenicos de bajo peso molecular de acido halurónico con toxinas polipeptidas

Country Status (15)

Country Link
US (1) US20020192205A1 (es)
EP (1) EP1385554A2 (es)
JP (1) JP2005508854A (es)
KR (1) KR20030096369A (es)
CN (1) CN1525869A (es)
AR (1) AR034331A1 (es)
BR (1) BR0209562A (es)
CA (1) CA2446555A1 (es)
CO (1) CO5550467A2 (es)
EC (1) ECSP034888A (es)
HU (1) HUP0400840A3 (es)
MX (1) MXPA03010283A (es)
PL (1) PL366692A1 (es)
SK (1) SK15122003A3 (es)
WO (1) WO2002092131A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物
US20070225484A1 (en) * 2006-03-25 2007-09-27 Framroze Bomi P Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
CA2773755C (en) * 2008-09-09 2017-04-25 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
CN102264444B (zh) * 2008-10-27 2015-08-05 诺华股份有限公司 纯化方法
CN102010469B (zh) * 2010-10-22 2013-02-27 上海贝西生物科技有限公司 一种抗透明质酸单克隆抗体及其用途
CN104302670A (zh) * 2012-02-07 2015-01-21 Phi生物医药股份有限公司 制造用于经皮给药的透明质酸-蛋白结合体的方法以及由该方法制造的用于经皮给药的透明质酸-蛋白结合体
CN104237500B (zh) * 2014-09-30 2016-09-28 博奥赛斯（天津）生物科技有限公司 一种透明质酸固相包被方法
EP3600442A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
IT201900022626A1 (it) * 2019-12-02 2021-06-02 Ub Care S R L Metodo per la determinazione del contenuto di sodio ialuronato in un idrogel
CN115590774B (zh) * 2022-10-20 2024-05-03 珠海原妙医学科技股份有限公司 透明质酸脂质体组装体及其制备方法和应用
CN119158011A (zh) * 2024-05-30 2024-12-20 江苏坤力生物制药有限责任公司 一种增强重组蛋白抗原免疫原性的方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
JPH0912600A (ja) * 1995-06-22 1997-01-14 Shiseido Co Ltd ヒアルロン酸ナトリウムに対するモノクローナル抗体及びその製造方法
CA2297072A1 (en) * 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
CA2332455C (en) * 1998-06-01 2012-08-14 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Also Published As

Publication number Publication date
BR0209562A (pt) 2004-03-30
WO2002092131A2 (en) 2002-11-21
US20020192205A1 (en) 2002-12-19
JP2005508854A (ja) 2005-04-07
HUP0400840A2 (hu) 2004-07-28
AR034331A1 (es) 2004-02-18
KR20030096369A (ko) 2003-12-24
CO5550467A2 (es) 2005-08-31
CA2446555A1 (en) 2002-11-21
HUP0400840A3 (en) 2004-10-28
CN1525869A (zh) 2004-09-01
SK15122003A3 (sk) 2004-10-05
WO2002092131A3 (en) 2003-03-20
EP1385554A2 (en) 2004-02-04
PL366692A1 (en) 2005-02-07
MXPA03010283A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
ECSP044933A (es) Método y montaje para aumentar el volumen del cabello
BR0315937A (pt) Composto, composição para a profilaxia ou tratamento de infecções virais, e, método para a profilaxia ou tratamento de infecções da hepatite c e doenças associadas com tais infecções em um hospedeiro vivo
EA200801570A1 (ru) Стабильные белковые препараты
BRPI0414176A (pt) inibidores de serina proteases, em particular hcv ns3-ns4a protease
BRPI0907087A2 (pt) ácidos nucleicos de fórmula (i) (nuglxmgnnv)a e derivados dos mesmos como um agente imunoestimulante/adjuvante
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
BR0210838A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
CO2022011947A2 (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
WO2002092131A3 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
BRPI0905687A8 (pt) composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
EA200701113A1 (ru) Макролиды
PE20251395A1 (es) Proteinas de fusion de hmpv de prefusion estabilizadas
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
DE69634961D1 (de) Neue zyklische depsipeptid pf1022 derivate
KR20240031857A (ko) Covid-19 백신을 임베딩하기 위한 파상풍 백신 플랫폼
BR0309753A (pt) Processo para a preparação de derivados de 6-alquilideno penem
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
BR0203949A (pt) Polipeptìdeo se36, processo para purificação do polipeptìdeo se36, vacina para malária, agente de diagnóstico para malária e fragmento de dna sintético
BR0014666A (pt) Vacina
PE20120116A1 (es) Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta hemolitica (bhs)